anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is being conducted to evaluate an investigational instrument called the HEM-AVERT™ Perianal Stabilizer and its efficacy in reducing the occurrence or severity of hemorrhoids and thrombosed external hemorrhoids (TEH). Hemorrhoids and TEH are caused by blood pooling in a distended vein and forming a clot, or thrombose, in the outer region of the anus. An anal fissure is a small split or tear in the anal mucosa that may result in painful bowel movements and bleeding. Like hemorrhoids, anal fissures are common in women after childbirth. Lacerations are graded as first, second, third and fourth degree. First and second degree are perineal lacerations and involve the mucosa and perineum and usually heal by themselves. First and second degree lacerations are considered to be a normal occurrence in child birth. Third degree lacerations involve the anal sphincter and fourth degree lacerations involve the sphincter and mucosa of the anus with bowel involvement and usually require surgical repair. Per the product classification that was assigned to this instrument by the FDA, the instrument is both non-invasive and posses a non-significant risk. It is classified as a manual, general instrument with no specific indications, but has a general indication of stabilizing pressure. The purpose of this clinical study is to collect data to support a 510(k) application to obtain the specific indication of preventing the occurrence of hemorrhoids, or reducing the severity of hemorrhoids which often occur during vaginal deliveries. Hemorrhoids and TEH represent common adverse events in vaginal births with reported occurrences ranging from a low of 9% to a high of 34% in the reported literature. Currently no preventative treatment exists. There will be two study groups; an investigational group (subjects receiving the HEM-AVERT™ instrument) and the control group (subjects will not receive the HEM-AVERT™ instrument). The HEM-AVERT™ Perianal Stabilizer is a Class 1, exempt device in accordance with FDA regulation 21 CFR 890.5765. The HEM-AVERT™ is a non-invasive instrument used to provide continuous pressure to the perianal region as a means to help provide support during the labor process. Each HEM-AVERT™ instrument is a single use, disposable, sterile, individually packaged instrument. The HEM-AVERT™ instrument consists of three components: 1) a rigid polymer base manufactured from a medical grade polycarbonate; 2) a centrally located cushioning pad which is composed of a laminate of medical grade polyester non-woven tape and medical grade polyethylene foam tape; and 3) two lateral hook and loop fastener adhesive strips (with liners) ("loop" strips that attach to the mating "hook" \[similar to VELCRO®\]) which is used to provide the tension needed to keep the instrument firmly in place during delivery. The cushioning pad and adhesive strips are manufactured using materials commonly found in medical instruments and used in medical procedures. All of the materials used to manufacture this instrument meet the available national or international standards specifications as applied to this instrument. This instrument is not to be implanted.
The invention discloses a monoclonal antibody EEEV-5E4 resisting an EEEV (Eastern Equine Encephalitis Virus) E2 protein, a B-cell epitope peptide recognized by the EEEV-5E4 as well as the application of the EEEV-5E4 and the B-cell epitope peptide. The invention further discloses a hybridoma cell strain which can stably secrete the EEEV-5E4 resisting the EEEV E2 protein and is named as EEEV-5E4. The microbial preservation number of the hybridoma cell strain is CGMCC No. 7008. An idiosyncratic reaction can occur between the EEEV-5E4 secreted by the hybridoma cell strain and the EEEV E2 protein while the EEEV-5E4 does not react with corresponding negative control. The EEEV-5E4 and the specific B-cell epitope peptide, recognized by the EEEV-5E4, of the EEEV E2 protein can be used for preparing reagents for identifying and diagnosing EEEVes/VEEVes (Western Equine Encephalitis Viruses/Venezuelan Equine Encephalitis Viruseses) and other alphaviruses and lay a foundation for creating serologic identifying and diagnosing methods of the EEEVes/VEEVes and other alphaviruses as well as further studying prevention and treatment measures of viruses relevant to alphaviruses.
PURPOSE:A hair tonic, containing a fatty acid having an odd number of carbon atoms or a derivative thereof as an active constituent, and capable of exhibiting high hair tonic effect. CONSTITUTION:A hair tonic containing a fatty acid having an odd number of carbon chain length or a derivative thereof as an active constituent. A monoglyceride, diglyceride, triglyceride, salt of a fatty acid, ester, amide, a dibasic acid and a salt thereof, sterol ester of formula I (R is straight chain organic group having an even number of carbon chain length), a phospholipid of formula II(at least one of R1 and R2 is straight chain organic group having an even number of carbon chain length; x is choline residue, etc.), phosphatidic acid, sphingolipid of formula III (X is saccharide residue, etc.), etc. may be cited as the above-mentioned derivative. The hair tonic exhibits improved hair tonic effect due to the following reasons: The fatty acid and derivative thereof is fat- soluble, easily migrates into sebum coexisting with hair follicle, and easily permeates into the hair root without directly affected by the action of hormones. The hair tonic exhibits particularly improved effects on male pattern alopecia and alopecia areata.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic capable of providing natural skin- colored finish in addition to action opacifying liver spot and freckles and safety by including red transparent powder and an alkyl-modified carboxyvinyl polymer. SOLUTION: This cosmetic comprises two components of (A) red transparent powder having (ii) red powder layer containing an organic red pigment on (i) base powder and having (iii) a layer containing translucent powder on the upper part and (B) an alkyl-modified carboxyvinyl polymer and/or physiologically permissible salt. The component (i) is preferably one or two or more kinds of substances selected from mica, sericite, etc., and is preferably contained in an amount of 1-40 wt.%. The component (ii) is preferably one or two or more kinds of substances selected from red pigment No.226, red pigment No.201, etc., and preferably contained in an amount of 1-40 wt.%. The component (iii) is preferably silica and is preferably contained in an amount of 20-70 wt.%. Preferable content of the component B is 0.01-5 wt.% based on total weight of the cosmetic.
This study is a randomized control trial with 10,000 participants. Participation will last for a minimum of 3 months and maximum of 8 months, depending upon COVID-19 case rates. Half of participants will be randomized to the control group and continue their existing testing and healthcare practices. The remaining participants will be randomized into the intervention arm. Participants in the intervention will receive one Cue Cartridge Reader for the duration of the study and up to 10 Cue COVID Molecular tests per month for their own use and to share with others in their household. In the case that a Cue Flu+COVID Molecular Test is available through FDA EUA or other authorization, participants may be provided this multiplex test in lieu of the Cue COVID Molecular Test. All intervention participants will be asked to test themselves if they are exposed or when symptoms arise and share tests with members of their household who are exposed to COVID or symptoms arise. The primary outcome will be the number of hospitalizations. This study will also compare infection rates, ICU admissions, deaths, and cost of care between the control and intervention group. The hypothesis is that access to high sensitivity portable molecular testing and subsequent telemedicine and prescription delivery can significantly decrease hospitalization and thereby the cost of care.

Interested individuals will access the study via the MyDataHelps platform by web or app to complete the eligibility and informed consent process. Within the MyDataHelps experience, participants will complete study activities such as surveys and sharing of claims data. Participants who are randomized to the intervention group will have the option to use Cue Care should they test positive for COVID-19. Cue Care contracts licensed Healthcare providers to deliver telemedicine and treatment for COVID-19. In the case that the COVID Flu+COVID test is available, the intervention group will also have the option to use Cue Care should they test positive for Influenza.

To learn more and take the eligibility survey, visit https://ImmunoCARE.scripps.edu/
A device obtains a series of measurements of a physiological parameter of a monitored patient when the device is operating within a monitoring workflow. The device displays a monitoring workflow home screen when the device is operating within the monitoring workflow. The monitoring workflow home screen contains a representation of the physiological parameter of the monitored patient. In addition, the device obtains a measurement of the physiological parameter of each patient in a series of patients when the device is operating within a non-monitoring workflow. The device displays a non-monitoring workflow home screen when the device is operating within the non-monitoring workflow. The non-monitoring workflow home screen contains a representation of the physiological parameter of a given patient in the series of patients.; The monitoring workflow home screen is different than the non-monitoring workflow home screen.
10% Sodium Sulfacetamide 5% Sulfur Cleanser (in a Urea vehicle). Wash affected area once or twice daily, or as directed by a physician. Avoid contact with eyes and mucous membranes. Wet skin and apply a generous amount to areas to be cleansed. Gently work into a full lather, massaging into the skin for 10-20 seconds. If drying of the skin occurs, it may be controlled by rinsing off the cleanser sooner or using less often.
The mono-calcium salt of phosphoric acid monoaminoethyl ester of the formula <FORM:1092185/C2/1> is prepared by treating 2-aminoethylphosphoric acid with calcium carbonate, other convenient soluble calcium salt, e.g. CaCl2 or calcium hydroxide.  The compound, which, from its high stability to hydrolysis, may have an internal ring structure, is a therapeutic agent of wide application.ALSO:Therapeutic compositions comprise the mono-calcium salt of phosphoric acid mono-aminoethyl ester, and magnesium and/or potassium aspartates.  Therapeutically acceptable diluents or extenders may also be present.  The compositions may take the form of aqueous vials for injection, liquid oral preparations, tablets, suppositories, lotions in aqueous resorbable solution, emulsion or ointment bases, or ophthalmic preparations.  They are stated to be useful in the treatment of a wide range of diseases and conditions.
An US guided subacromial injection (1 cc of corticostheroid ) and anesthetic (2 cc of mepivacaine) will be performed. The periodicity will be one infiltration every 8-10 weeks, being able to carry out a maximum of 3 per year.
The invention discloses an avian influenza virus TJ strain, an avian influenza inactivated vaccine and a preparation method thereof. The invention separates and obtains a strain of avian influenza virus TJ strain from a certain culture field in suburb of Tianjin, and the microorganism preservation number is CGMCC NO. 14323. The virus isolate TJ strain provided by the invention HAs certain difference with HA and NA amino acid sequences of the existing JY strain and HZ strain, and the bird flu virus TJ strain separated by the invention HAs 4 titers higher than the existing HZ strain and 3 titers higher than the existing JY strain in HI antibody titer. The invention further applies the avian influenza virus TJ strain to prepare the avian influenza inactivated vaccine. The potency test result of the inactivated vaccine is that the geometric mean values of HI antibody titers of two groups of immunization groups of chickens are respectively 7.5log2 and 8.2log2, and the immune protection potency evaluation test result of the inactivated vaccine shows that the inactivated vaccine can provide good protection against the attack of avian influenza virus.
Routine opioid protocol of anesthesia provided for induction of anesthesia with the iv administration of propofol dosage of 1.5-2 mg/kg at 40 mg in interval of 15-20 seconds, iv fentanyl at a dose of 1-1.5 μg/kg and iv pipecuronium bromide dosage of 0.1 mg/kg. For analgesia, bolus injections of fentanyl were used at a dose of 8-10 μg/kg for the entire duration of the operation, muscle relaxation - pipecuronium bromide at a dose of 0.1 mg/kg. Depth of anesthesia was monitored with bispectral index; the dosage of sevoflurane from 1,5vol% to 2,5vol% was titrated to maintain BIS values from 40 to 60.
Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to medicine, namely to oncology and can be used for oncotherapy. The inventions cover methods, a composition and a kit for blocking or reducing tumour or malignant cell growth. According to the inventions, treatment includes administration of angiopoietin-like protein 4 (ANGPTL4) antagonist both alone, and with antiangiogenic agents, particularly with vascular endotheliocyte growth factor (VEGF) antagonist. ^ EFFECT: use of the inventions allows improving effectiveness in tumour growth inhibition due to reduced ANGPTL4 activity ensured by the antagonist. ^ 40 cl, 2 tbl, 7 ex
Participating radiologists will perform clinical reading on \~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
A system extrapolates and interpolates patient fluid intake or output parameter values and associated cumulative values over variable time intervals from a reduced set of stored fluid parameter values affecting fluid cumulative volume computation or rate of fluid intake or output computation. The extrapolation and interpolation function accomodates drip (continuing) fluid volumes as well as supplemental (non-continuing e.g., bolus) fluid volumes. A patient medical parameter data processing system provides patient medical parameter data for trend indicative display covering a time period comprising user selectable patient parameter acquisition time intervals. The system includes an acquisition processor for receiving data identifying, for a continuing infusion, rate of volume of fluid infusion into a patient, a fluid type identifier and a start time and start date of said continuing infusion. The received data also identifies for a non-continuing infusion, a total volume of fluid infusion, a fluid type identifier and a time and date of the non-continuing infusion. A data processor determines, from the received data, a cumulative total volume infusion of a particular fluid into a particular patient for a particular user selectable patient parameter acquisition time interval.
OBJECTIVE: The aim of the investigation was to compare patients hospitalized with SARS-CoV-2 infection during 2020/2021 and 2022 with respect to the reason for hospitalization as well as severity of disease at admission, during follow-up and clinical outcomes.
METHODS: The data of all patients patients hospitalized with SARS-CoV-2 infection during the periods of interest were collected. Severity of disease at admission and during follow-up was compared in all patients who were hospitalized because of SARS-CoV-2 infection.
RESULTS: During the period of 2020 to 2021, overall n=1281 patients with SARS-CoV-2 infection were hospitalized as compared to n=580 in 2022. Of these, 90% and 42%, respectively, were admitted because of SARS-CoV-2 infection. The rates of nosocomial transmission increased from 5 to 18%. Severity of disease at admission and during follow-up was higher across all age groups in the first period. More patients were admitted to the ICU (25 versus 4%). Accordingly, hospital mortality was higher (17 versus 10%). Intubated patients had a high mortality of 74 and 80%, respectively, in both periods.
CONCLUSIONS: The severity at admission and during follow-up was much higher in the first period. In the second period, the burden of health care systems was only in part driven by disease severity but more by the need for isolation and nosocomial infections. Mortality of intubated patients was high.
BACKGROUND: Mitochondrial dysfunction occurs in monocytes during obesity and contributes to a low-grade inflammatory state; therefore, maintaining good mitochondrial conditions is a key aspect of maintaining health. Dietary interventions are primary strategies for treating obesity, but little is known about their impact on monocyte bioenergetics. Thus, the aim of this study was to evaluate the effects of calorie restriction (CR), intermittent fasting (IF), a ketogenic diet (KD), and an ad libitum habitual diet (AL) on mitochondrial function in monocytes and its modulation by the gut microbiota.
METHODS AND FINDINGS: A randomized controlled clinical trial was conducted in which individuals with obesity were assigned to one of the 4 groups for 1 month. Subsequently, the subjects received rifaximin and continued with the assigned diet for another month. The oxygen consumption rate (OCR) was evaluated in isolated monocytes, as was the gut microbiota composition in feces and anthropometric and biochemical parameters. Forty-four subjects completed the study, and those who underwent CR, IF and KD interventions had an increase in the maximal respiration OCR (p = 0.025, n2p = 0.159 [0.05, 0.27] 95% confidence interval) in monocytes compared to that in the AL group. The improvement in mitochondrial function was associated with a decrease in monocyte dependence on glycolysis after the IF and KD interventions. Together, diet and rifaximin increased the gut microbiota diversity in the IF and KD groups (p = 0.0001), enriched the abundance of Phascolarctobacterium faecium (p = 0.019) in the CR group and Ruminococcus bromii (p = 0.020) in the CR and KD groups, and reduced the abundance of lipopolysaccharide (LPS)-producing bacteria after CR, IF and KD interventions compared to the AL group at the end of the study according to ANCOVA with covariate adjustment. Spearman's correlation between the variables measured highlighted LPS as a potential modulator of the observed effects. In line with this findings, serum LPS and intracellular signaling in monocytes decreased with the three interventions (CR, p = 0.002; IF, p = 0.001; and KD, p = 0.001) compared to those in the AL group at the end of the study.
CONCLUSIONS: We conclude that these dietary interventions positively regulate mitochondrial bioenergetic health and improve the metabolic profile of monocytes in individuals with obesity via modulation of the gut microbiota. Moreover, the evaluation of mitochondrial function in monocytes could be used as an indicator of metabolic and inflammatory status, with potential applications in future clinical trials.
TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov (NCT05200468).
<P>PROBLEM TO BE SOLVED: To obtain functional olive oil containing polyphenol in ≥60% residual ratio based on raw material oil and to provide a use thereof.  <P>SOLUTION: The functional olive oil is obtained by a production method with which only physical operations are performed and no chemical treatment is carried out from oil collection from olive fruits to deodorization treatment, is of a type much containing active ingredients in spite of having no flavor characteristic of olive and contains polyphenol preferably in ≥60% residual ratio based on raw material oil. The method for producing functional olive oil comprises (a) a process for collecting oil from olive fruits and (b) a process for removing a smell component from the obtained oil by a distillation means and carrying out only physical treatments without chemical treatment at all from the process (a) to the process (b). The in vivo antioxidant composition comprises the functional olive oil as an active ingredient. The in vivo antioxidant composition is selected from the group consisting preferably of seasoning, food additive, food material, food and beverage, health food and beverage, external preparation for skin, medicine and feed.  <P>COPYRIGHT: (C)2007,JPO&INPIT
This is a prospective, single site study. Ocular history and examination will be conducted on consented subjects to determine further participation in the study. The study will be divided into two phases. In Phase 1, the inter-device variability of Cirrus HD-OCT measurements of illumination areas under the RPE will be determined. In Phase 2, the inter-operator variability of Cirrus HD-OCT measurements of illumination areas under the RPE will be determined. In each of these phases, the Macular Cube 200 x 200 scan and the Macular Cube 512 x 128 scan will be evaluated.
Target organs of linezolid toxicity were similar in juvenile and adult rats and dogs. Dose- and time-dependent myelosuppression, as evidenced by bone marrow hypocellularity/decreased hematopoiesis, decreased extramedullary hematopoiesis in spleen and liver, and decreased levels of circulating erythrocytes, leukocytes, and platelets have been seen in animal studies. Lymphoid depletion occurred in thymus, lymph nodes, and spleen. Generally, the lymphoid findings were associated with anorexia, weight loss, and suppression of body weight gain, which may have contributed to the observed effects.  
In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change.   
These effects were observed at exposure levels that are comparable to those observed in some human subjects. The hematopoietic and lymphoid effects were reversible, although in some studies, reversal was incomplete within the duration of the recovery period.